A Phase 3 interventional study of Aliskiren and Amlodipine in Essential Hypertension, sponsored by Novartis. Completed at 8 sites in 8 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2021-06-07.
Sponsored by Novartis · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 34 studies testing amlodipine in Essential Hypertension — 1 open to participants now, 1 under way, none of them phase 3. Amlodipine · Essential Hypertension.
Among the 34 studies testing amlodipine in Essential Hypertension, this one is the 7th largest by enrollment, is the only one that started in 2008, is one of 18 in phase 3, and was the 5th registered.
481 studies on the registry are indexed under Essential Hypertension; 77 are open to participants now.
Browse Essential Hypertension studies →1 of the 34 studies testing amlodipine in Essential Hypertension is open now, in 1 country. Recruiting first, the newest first:
Radboud University Medical Center · Sites in Netherlands
Ages 18–75
By country, each count listing its studies:
Amlodipine: first FDA approval 1992 (NORVASC), first EMA approval 2007. What it is approved for, and how studies give it, is on its page →
Of the 45 Essential Hypertension studies recruiting now, 17 (38%) set no upper age limit and 20 (44%) stop at 75 or younger; 4 take children under 18; 11 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
34 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 1 · Phase 2 5 · Phase 3 19 · Phase 4 7
First in 2005; this study’s year is marked. 1 started in 2008.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 564 is above the median of 144 across 408 interventional studies indexed under Essential Hypertension.
Median enrollment 314 across the 34 interventional studies. Of the 30 that completed or were terminated, 7 (23%) have results posted.
This tab as a report to print or save as PDF → With an account.
27 of 34 have an industry lead sponsor. The 10 most frequent:
Novartis is the lead sponsor of 714 studies on the registry; none are open to participants now.
27 studies in Essential Hypertension by Novartis: none open now, none under way, none of them phase 3. Of 27 finished, 19 (70%) have results posted.
Among the 27 studies in Essential Hypertension by Novartis, this one is the 12th largest by enrollment of the 25 interventional ones that give a count, is one of 5 that started in 2008, is one of 15 in phase 3, and was the 7th registered.
Novartis’s Essential Hypertension studies by the year they started, since 2005.
None of the studies under way reaches primary completion within a year.
Among the 34 studies testing amlodipine in Essential Hypertension, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Novartis’s 27 in Essential Hypertension:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This study tested the safety of the combination of aliskiren/amlodipine/hydrochlorothiazide in participants with essential hypertension.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Mean sitting diastolic blood pressure (msDBP) and mean sitting systolic blood pressure (msSBP) Requirements:
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Washout period
A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants received aliskiren 300 milligrams (mg) plus hydrochlorothiazide 12.5 mg for one week, at Week 1 followed by combination of aliskiren 300 mg plus amlodipine 5 mg plus hydrochlorothiazide 12.5 mg for one week, at Week 2. Following Week 2, participants were force titrated up to aliskiren 300 mg plus amlodipine 10 mg plus hydrochlorothiazide 25 mg for 26 to 52 weeks (Weeks 28 to 54). All study medications were taken orally with water, once daily in the morning.
Drug: Aliskiren · Drug: Amlodipine · Drug: Hydrochlorothiazide
300 mg tablet
5 mg tablet
12.5 mg and 25 mg capsule
Number of Participants With Any Adverse Events (AEs), Serious Adverse Events (SAEs) and Death
An AE was defined as the appearance or worsening of any undesirable sign, symptom, or medical condition occurring after starting the study drug, even if the event is not considered to be related to study drug. An SAE was defined as an event which was fatal or life-threatening, resulted in persistent or significant disability/incapacity, constituted a congenital anomaly/birth defect, required inpatient hospitalization or prolongation of existing hospitalization, was medically significant, i.e. defined as an event that jeopardizes the participant or may require medical or surgical intervention to prevent one of the outcomes listed above.
Time frame: 54 weeks
Change From Baseline in Mean Sitting Diastolic Blood Pressure (msDBP)
The arm in which the highest sitting diastolic pressures were found at study entry was the arm used for all subsequent readings. A calibrated sphygmomanometer and appropriate size cuff were used to measure arterial sitting blood pressure (BP) at trough with the arm supported at the level of the heart. At each study visit, after having the participant in a sitting position for five minutes, systolic/diastolic blood pressure were measured 3 times at 1-2 minute intervals. A mean was calculated from the 3 measurements. A negative change indicates improvement. Week 28 Endpoint was the last non-missing post-baseline measurement value on or before Week 28, and Week 54 Endpoint was the last non-missing measurement value after Week 28.
Time frame: Baseline, Weeks 28 and 54 endpoint
Change From Baseline in Mean Sitting Systolic Blood Pressure (msSBP)
The arm in which the highest sitting diastolic pressures were found at study entry was the arm used for all subsequent readings. A calibrated sphygmomanometer and appropriate size cuff were used to measure arterial sitting blood pressure (BP) at trough with the arm supported at the level of the heart. At each study visit, after having the participant in a sitting position for five minutes, systolic/diastolic blood pressure were measured 3 times at 1-2 minute intervals. A mean was calculated from the 3 measurements. A negative change indicates improvement. Week 28 Endpoint was the last non-missing post-baseline measurement value on or before Week 28, and Week 54 Endpoint was the last non-missing measurement value after Week 28.
Time frame: Baseline, Weeks 28 and 54 endpoints
Percentage of Participants Achieving the Blood Pressure Control Target of <140/90 mmHg
Blood pressure control was defined as having a mean sitting diastolic blood pressure \<90 mmHg and a mean sitting systolic blood pressure \<140 mmHg. Percentage of participants achieving the blood pressure control of \< 140/90 mmHg were reported. Week 28 Endpoint was the last non-missing post-baseline measurement value on or before Week 28 and Week 54 Endpoint was the last non-missing measurement value after Week 28.
Time frame: Weeks 28 and 54 endpoints
Percentage of Participants Who Achieved a Blood Pressure Response in Mean Sitting Diastolic Blood Pressure
Diastolic Blood pressure response was defined as a mean sitting diastolic blood pressure \<90 mmHg or a \>=10 mmHg reduction from baseline value. Week 28 Endpoint was the last non-missing post-baseline measurement value on or before Week 28, and Week 54 Endpoint was the last non-missing measurement value after Week 28.
Time frame: Weeks 28 and 54 endpoints
Percentage of Participants Who Achieved a Blood Pressure Response in Mean Sitting Systolic Blood Pressure
Systolic blood pressure response was defined as a mean sitting systolic blood pressure \<140 mmHg or a \>=20 mmHg reduction from baseline value. Week 28 Endpoint was the last non-missing post-baseline measurement value on or before Week 28, and Week 54 Endpoint was the last non-missing measurement value after Week 28.
Time frame: Weeks 28 and 54 endpoints
Participants with essential hypertension were enrolled in the study at 82 investigative sites worldwide from 5 June 2008 to 5 October 2009.
| Milestone | Aliskiren /Amlodipine/Hydrochlorothiazide |
|---|---|
| Started | 564 |
| Completed | 493 |
| Not completed | 71 |
| Withdrew: Adverse event | 39 |
| Withdrew: Abnormal test procedure | 1 |
| Withdrew: Unsatisfactory therapeutic effect | 3 |
| Withdrew: Protocol violation | 3 |
| Withdrew: Withdrawal by subject | 17 |
| Withdrew: Lost to follow-up | 8 |
An AE was defined as the appearance or worsening of any undesirable sign, symptom, or medical condition occurring after starting the study drug, even if the event is not considered to be related to study drug. An SAE was defined as an event which was fatal or life-threatening, resulted in persistent or significant disability/incapacity, constituted a congenital anomaly/birth defect, required inpatient hospitalization or prolongation of existing hospitalization, was medically significant, i.e. defined as an event that jeopardizes the participant or may require medical or surgical intervention to prevent one of the outcomes listed above.
| Participants | Aliskiren/Hydrochlorothiazide 300/12.5 mg | Aliskiren/Amlodipine/Hydrochlorothiazide 300/5/12.5 mg | Aliskiren/Amlodipine/Hydrochlorothiazide 300/10/25 mg |
|---|---|---|---|
| Any Adverse Events | 57 | 54 | 255 |
| Serious Adverse Events | 0 | 1 | 14 |
| Death | 0 | 0 | 0 |
The arm in which the highest sitting diastolic pressures were found at study entry was the arm used for all subsequent readings. A calibrated sphygmomanometer and appropriate size cuff were used to measure arterial sitting blood pressure (BP) at trough with the arm supported at the level of the heart. At each study visit, after having the participant in a sitting position for five minutes, systolic/diastolic blood pressure were measured 3 times at 1-2 minute intervals. A mean was calculated from the 3 measurements. A negative change indicates improvement. Week 28 Endpoint was the last non-missing post-baseline measurement value on or before Week 28, and Week 54 Endpoint was the last non-missing measurement value after Week 28.
| mmHg | Aliskiren/Amlodipine/Hydrochlorothiazide |
|---|---|
| Baseline | 101.8 ± 7.74 |
| Change from Baseline to Week 28 Endpoint | -20.3 ± 8.92 |
| Change from Baseline to Week 54 Endpoint | -21.8 ± 8.66 |
The arm in which the highest sitting diastolic pressures were found at study entry was the arm used for all subsequent readings. A calibrated sphygmomanometer and appropriate size cuff were used to measure arterial sitting blood pressure (BP) at trough with the arm supported at the level of the heart. At each study visit, after having the participant in a sitting position for five minutes, systolic/diastolic blood pressure were measured 3 times at 1-2 minute intervals. A mean was calculated from the 3 measurements. A negative change indicates improvement. Week 28 Endpoint was the last non-missing post-baseline measurement value on or before Week 28, and Week 54 Endpoint was the last non-missing measurement value after Week 28.
| millimeters of mercury | Aliskiren/Amlodipine/Hydrochlorothiazide |
|---|---|
| Baseline | 166.1 ± 11.59 |
| Change from baseline to Week 28 Endpoint | -34.2 ± 14.16 |
| Change from Baseline to Week 54 Endpoint | -37.3 ± 14.63 |
Blood pressure control was defined as having a mean sitting diastolic blood pressure \<90 mmHg and a mean sitting systolic blood pressure \<140 mmHg. Percentage of participants achieving the blood pressure control of \< 140/90 mmHg were reported. Week 28 Endpoint was the last non-missing post-baseline measurement value on or before Week 28 and Week 54 Endpoint was the last non-missing measurement value after Week 28.
| percentage of participants | Aliskiren/Amlodipine/Hydrochlorothiazide |
|---|---|
| Week 28 Endpoint | 69.1 |
| Week 54 Endpoint | 77.1 |
Diastolic Blood pressure response was defined as a mean sitting diastolic blood pressure \<90 mmHg or a \>=10 mmHg reduction from baseline value. Week 28 Endpoint was the last non-missing post-baseline measurement value on or before Week 28, and Week 54 Endpoint was the last non-missing measurement value after Week 28.
| percentage of participants | Aliskiren/Amlodipine/Hydrochlorothiazide |
|---|---|
| Week 28 Endpoint | 91.8 |
| Week 54 Endpoint | 96.6 |
Systolic blood pressure response was defined as a mean sitting systolic blood pressure \<140 mmHg or a \>=20 mmHg reduction from baseline value. Week 28 Endpoint was the last non-missing post-baseline measurement value on or before Week 28, and Week 54 Endpoint was the last non-missing measurement value after Week 28.
| percentage of participants | Aliskiren/Amlodipine/Hydrochlorothiazide |
|---|---|
| Week 28 Endpoint | 90.2 |
| Week 54 Endpoint | 93.7 |
Collected over From Baseline up to 54 weeks.. Non-serious events are listed at a 2% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Aliskiren/Hydrochlorothiazide 300/12.5 mg | 0/564 (0%) | 0/564 (0%) | 21/564 (3.7%) |
| Aliskiren/Amlodipine/Hydrochlorothiazide 300/5/12.5 mg | 0/561 (0%) | 1/561 (0.2%) | 14/561 (2.5%) |
| Aliskiren/Amlodipine/Hydrochlorothiazide 300/10/25 mg | 0/556 (0%) | 14/556 (2.5%) | 141/556 (25.4%) |
| Event | Aliskiren/Hydrochlorothiazide 300/12.5 mg | Aliskiren/Amlodipine/Hydrochlorothiazide 300/5/12.5 mg | Aliskiren/Amlodipine/Hydrochlorothiazide 300/10/25 mg |
|---|---|---|---|
| PalpitationsCardiac disorders | 0/564 | 0/561 | 2/556 |
| ThrombocytopeniaBlood and lymphatic system disorders | 0/564 | 0/561 | 1/556 |
| Atrial fibrillationCardiac disorders | 0/564 | 0/561 | 1/556 |
| Inguinal hernia, obstructiveGastrointestinal disorders | 0/564 | 0/561 | 1/556 |
| Non-cardiac chest painGeneral disorders | 0/564 | 0/561 | 1/556 |
| BronchitisInfections and infestations | 0/564 | 0/561 | 1/556 |
| SinusitisInfections and infestations | 0/564 | 0/561 | 1/556 |
| ArthritisMusculoskeletal and connective tissue disorders | 0/564 | 0/561 | 1/556 |
| Cervical spinal stenosisMusculoskeletal and connective tissue disorders | 0/564 | 0/561 | 1/556 |
| Intervertebral disc protrusionMusculoskeletal and connective tissue disorders | 0/564 | 0/561 | 1/556 |
| Event | Aliskiren/Hydrochlorothiazide 300/12.5 mg | Aliskiren/Amlodipine/Hydrochlorothiazide 300/5/12.5 mg | Aliskiren/Amlodipine/Hydrochlorothiazide 300/10/25 mg |
|---|---|---|---|
| Oedema peripheralGeneral disorders | 1/564 | 0/561 | 52/556 |
| NasopharyngitisInfections and infestations | 3/564 | 2/561 | 20/556 |
| BronchitisInfections and infestations | 2/564 | 3/561 | 16/556 |
| InfluenzaInfections and infestations | 0/564 | 0/561 | 15/556 |
| HeadacheNervous system disorders | 10/564 | 6/561 | 15/556 |
| Back painMusculoskeletal and connective tissue disorders | 0/564 | 2/561 | 12/556 |
| DiarrhoeaGastrointestinal disorders | 5/564 | 1/561 | 11/556 |
Treated Population consisted of all participants who received at least one dose of trial medication.
| Age, Continuous(years) | Aliskiren /Amlodipine/Hydrochlorothiazide |
|---|---|
| Mean | 55.9 ± 11.34 |
| Sex: Female, Male(Participants) | Aliskiren /Amlodipine/Hydrochlorothiazide |
|---|---|
| Female | 238 |
| Male | 326 |
Ran from Jun 2008 to primary completion in Oct 2009, 16 months.
Results were first posted in Jun 2021, 11 years 8 months after primary completion.
Of 45 industry-sponsored phase 3 interventional studies under Essential Hypertension, half reached primary completion within 16 months of starting (the median), counting those still running; a quarter within 11 and three quarters within 24. This study's 16 months is close to that.
Counting every sponsor, half of 47 studies reached it within 17 months; a quarter within 11 and three quarters within 24.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in May 2021. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Aliskiren · Amlodipine · Hydrochlorothiazide